Novavax begins mid-stage study of COVID-19 vaccine in South Africa

Published on 17 Aug 2020 9:52:47 PM

U.S. drug developer Novavax Inc said on Monday that it is starting a mid-stage study of its experimental COVID-19 vaccine in South Africa, as the country experiences a surge in coronavirus cases.

In a statement, the company said the Phase 2b trial study of NVX-CoV2373 will be conducted on about 2,665 healthy adults and will evaluate the safety and immunogenicity in about 240 medically stable, HIV-positive adults

Read more: